



DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 6, 2007 – At the 2nd Annual General Meeting of DOTTIKON ES HOLDING AG for the business year 2006/07 carried out at the "Kultur- und Kongresszentrum Trafo" in Baden, the shareholders approved all proposals of the Board of Directors. 185 present shareholders represented 1'044'361 voting rights and therefore 90.7% of the total of 1'150'913 registered shares with voting rights.

The annual report, financial statements 2006/07 and the consolidated financial report 2006/07 of the DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the dividend payment of CHF 8.00 per share entitled to dividends was accepted with great majority. Discharge for the business year 2006/07 was granted to the responsible Board of Directors and Management. All members of the Board, Heinz Boller, Dr. h.c. Peter Grogg and Dr. Robert Hofer, are reelected for an additional term of one year. Group auditors and statutory auditors for the present term is KPMG AG, Zurich.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), specializes on hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

For further information please contact

Rémy Scheidegger
Senior Assistant to CEO

DOTTIKON ES HOLDING AG
Tel +41 56 616 82 01
Fax +41 56 616 89 45
remy.scheidegger@dottikon.com